Premium
Improving outcomes for patients with acute myeloid leukemia in first relapse: A single center experience
Author(s) -
Pemmaraju Naveen,
Kantarjian Hagop,
GarciaManero Guillermo,
Pierce Sherry,
CardenasTuranzas Marylou,
Cortes Jorge,
Ravandi Farhad
Publication year - 2015
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.23858
Subject(s) - medicine , myeloid leukemia , oncology , clinical trial , single center , disease , intensive care medicine
The outcome of patients with relapsed acute myeloid leukemia (AML) remains unsatisfactory, with few available effective therapies. Increased understanding of the biology of the disease has led to the identification of novel therapeutic agents, several of which have been evaluated in recently conducted clinical trials. We sought to determine whether the introduction of these agents as well as modern supportive care measures has already translated to better outcomes. We examined the outcomes of 1,056 patients with AML in first relapse treated between January 1993 and December 2013 at our institution. As previously reported, the independent prognostic factors for survival after first relapse included age at relapse, cytogenetics, and duration of first complete remission. Upon multivariable analysis, treatment era was an independent predictor of survival, with significant improvement in overall survival between 2008 and 2013 as compared to prior time periods. Modern supportive care measures as well as participation in clinical trials of novel agents are already improving the outcomes in first relapse. Am. J. Hematol. 90:27–30, 2015. © 2014 Wiley Periodicals, Inc.